Insider · CIK 0001880034
Priti Hegde
Files at ADAPY (Adaptimmune Therapeutics PLC), TCRR (TCR2 THERAPEUTICS INC.). First filing -, latest -.
In brief
Priti Hegde files SEC Form 4 as director at ADAPY (Adaptimmune Therapeutics PLC), and also at TCRR (TCR2 THERAPEUTICS INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Priti Hegde has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2024 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to purchase Ordinary Sharesderivative | +1,144,686 | $0.00 | $0 | 1,144,686 | Jul 1, 2024 |
| Jul 5, 2023 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to Purchase Ordinary Sharesderivative | +226,464 | $0.00 | $0 | 226,464 | Jul 5, 2023 |
| Jul 5, 2023 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to Purchase Ordinary Sharesderivative | +109,746 | $0.00 | $0 | 109,746 | Jul 5, 2023 |
| Jul 5, 2023 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to Purchase Ordinary Sharesderivative | +152,376 | $0.00 | $0 | 152,376 | Jul 5, 2023 |
| Jul 3, 2023 | ADAPY Adaptimmune Therapeutics PLC | AGrant or award Option to purchase Ordinary Sharesderivative | +500,000 | $0.00 | $0 | 500,000 | Jul 3, 2023 |
| Jun 1, 2023 | TCRR TCR2 THERAPEUTICS INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,800 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | TCRR TCR2 THERAPEUTICS INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,100 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Jun 1, 2023 | TCRR TCR2 THERAPEUTICS INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -24,968 | $0.00 | $0 | 0 | Jun 1, 2023 |
| Dec 15, 2022 | TCRR TCR2 THERAPEUTICS INC. | AGrant or award Stock Option (Right to Buy)derivative | +16,800 | $0.00 | $0 | 16,800 | Dec 19, 2022 |
Questions about Priti Hegde
Answered from the filings on this page, as of the latest one.
Is Priti Hegde buying or selling?
Priti Hegde has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Priti Hegde's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Priti Hegde has 0.
Where does Priti Hegde file Form 4?
Priti Hegde has filed Form 4 at ADAPY (Adaptimmune Therapeutics PLC); TCRR (TCR2 THERAPEUTICS INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.